BIRC5 and non-small cell lung carcinoma: Another study showed that the BIRC5 protein was strongly expressed in NSCLC afatinib resistant cell lines, and the use of BRCA5 inhibitor YM155 can lead to increased NSCLC sensitivity to afatinib44.